Hajime Iizuka, Hokkaido; Satoru Aoyagi, Hokkaido; Ryuhei Okuyama, Miyagi; Masakazu Kawaguchi, Yamagata; Mamitaro Ohtsuki, Tochigi; Masatoshi Abe, Gunma; Kenji Takamori, Shoichi Matsuba, Chiba; Tadashi Terui, Tokyo; Atsuyuki Igarashi, Tokyo; Makoto Kawashima, Tokyo; Masayuki Amagai, Yujiro Takae, Tokyo; Hikaru Eto, Tokyo; Takafumi Etoh, Tokyo; Shigaku Ikeda, Tokyo; Mayumi Komine, Hidehisa Saeki, Tokyo; Kazuhito Hayakawa, Tokyo; Amane Kitami, Tokyo; Akihiko Asahina, Kanagawa; Akira Ozawa, Kanagawa; Kazuhiko Takehara, Ishikawa; Shinji Shimada, Yamanashi; Yasuo Kitajima, Gifu; Masahiro Takigawa, Shizuoka; Akimichi Morita, Aichi; Keiichi Yamanaka, Mie; Masahito Tarutani, Mamori Tani, Osaka; Masahiko Muto, Yamaguchi; Yasuo Kubota, Kagawa; Juichiro Nakayama, Fukuoka; Masutaka Furue, Fukuoka; Shinichi Sato, Nagasaki.
Long-term study of infliximab in Japanese patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma
Article first published online: 2 SEP 2010
© 2010 Japanese Dermatological Association
The Journal of Dermatology
Volume 38, Issue 4, pages 321–334, April 2011
How to Cite
TORII, H., NAKAGAWA, H. and THE JAPANESE INFLIXIMAB STUDY INVESTIGATORS (2011), Long-term study of infliximab in Japanese patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma. The Journal of Dermatology, 38: 321–334. doi: 10.1111/j.1346-8138.2010.00971.x
Declaration of conflict of interest: This study was sponsored by Mitsubishi Tanabe Pharma, Osaka, Japan. Hideshi Torii and Hidemi Nakagawa have received research support from and served as consultants for Mitsubishi Tanabe Pharma.
- Issue published online: 22 MAR 2011
- Article first published online: 2 SEP 2010
- Received 8 February 2010; accepted 24 March 2010.
- psoriatic arthritis;
- psoriatic erythroderma;
- pustular psoriasis;
- tumor necrosis factor-α
The efficacy and safety of infliximab in patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis (excluding localized type) and psoriatic erythroderma were assessed in clinical practice. Without washout of the existing treatment of psoriasis, treatment was switched to infliximab, which was given at a dose of 5 mg/kg at weeks 0, 2 and 6 and then every 8 weeks up to week 46. The primary end-points were 75% improvement in Psoriasis Area and Severity Index score (PASI 75 response rate) for plaque psoriasis, 20% improvement in American College of Rheumatology criteria (ACR 20 response rate) for psoriatic arthritis, and global improvement in pustular psoriasis and psoriatic erythroderma. The PASI 75 response rate in plaque psoriasis was 72.2% at week 10 and 53.6% at week 50. The ACR 20 response rate in psoriatic arthritis was 66.7% at week 14 and 80.0% at week 46. The response defined as global improvement in pustular psoriasis was between 66.7% and 100.0% during the 2–50-week period. The response defined as global improvement in psoriatic erythroderma was between 75.0% and 100.0% during the week-2–50 period. There were 14 discontinued patients. The most frequently reported reason for discontinuation was the development of adverse events. However, there were no serious respiratory diseases, infections or infusion reactions. In patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma, infliximab was well tolerated, regardless of prior treatment, and also showed superior efficacy over a period of approximately 1 year.